It therefore begs the question why OMF feels compelled to defend the use of the term at this time.
From the news item:
I understand that this is a complicated and sometimes controversial topic, so before I get into it, let me acknowledge that complexity and say that we do our best to reflect the voices and experiences of the people we are trying to serve.
While the term multi-system chronic complex disease is perhaps overwhelming at first, each component is relatively straightforward when you break it down.

OMF seems to be acknowledging that they have received push-back, that the term is controversial. But, they seem to be doubling down on the term. The word 'complex' is in bold on the OMF home page. Doctors who are members of the forum have confirmed how the word 'complex' is received by many doctors, it plays into the way ME/CFS is seen by BPS proponents. We've told OMF researchers about the impact of that on people with ME/CFS. OMF doesn't just seem to be ignoring that, they seem to be suggesting that people who disagree with them are just overwhelmed and need things explained in very simple terms.

Complex diseases require open collaboration
ME/CFS and Long COVID disrupt many body systems. Traditional research looks at one system at a time. That approach doesn’t work.

That’s where Open Medicine Foundation (OMF) comes in. OMF brings world-renowned scientists together to study, diagnose, treat, and cure complex diseases.

It’s a bold dream. It’s the path that will get you back to a fulfilling life.
OMF believes multisystem disease should not be a life sentence but a solvable puzzle.
What will happen if research remains focused on one system at a time?
How will your life shrink? How many graduations, birthday parties, or everyday activities will you miss? What will happen with your career?
Something has to change.

OMF also makes a big deal about how they see ME/CFS as a multi-system disease, and suggests that funding researchers to look at a range of body systems is some ground-breaking approach. The suggestion that ME/CFS research outside of OMF is 'remaining focussed on one system at a time' and that they are the only organisation looking wider, is just not supported by reality. Researchers, some good and some bad, some within the OMF stable and some not, are looking at a wide range of 'systems' and clearly talk to each other, in conferences and elsewhere.

That OMF home page does not work for me, and does not seem to me to be grounded in truth. But, clearly it is what OMF has chosen, and perhaps it is working for them. So I guess each to their own.
 
Hello! I have been away from S4ME for a while. I have tried unsuccessfully to get funding in the UK to pursue my Trialblazers idea (2 pager and 4 pager attached) which is about how to get patients en masse involved in designing clinical trials. I want to use designing a trial of one or more repurposed drugs for ME as a case-study/proof of concept. I would love to collaborate with OMF/CTN Lite if possible to get this idea off the ground. Funnily enough I was already considering travelling to California this summer to visit my daughter who will be doing an internship at Caltech in Pasadena. Not far from where OMF is based?? Is anyone from OMF/CTN Lite on here and interested in talking to me? If not, should I just write to OMF info@omf.ngo? Any advice gratefully received
I emailed OMF and Linda Tannenbaum said she would discuss my ideas with Danielle Meadows. They are not around when I'm in California - Danielle is based elsewhere in the US anyway. I'm not sure they are taking me too seriously as they were in Cambridge UK a week or so ago, and I would have loved to meet them if they'd let me know they were coming. I think probably they didn't twig I was based in the UK, and I don't think they necessarily need my help or input with CTN Lite anyway.

I think my next move is to try and work on the technical side of developing a citizen science platform to enable crowd-sourcing of trial design by potential trial participants from any patient group (trial setting, choosing outcomes, objective outcome measures, setting the minimally important effect size, ways to minimize participant burden etc.) - I won't focus specifically on ME. I think this approach would lend itself to large trials of repurposed drugs (found to be safe in other contexts) for ME and other long-term conditions where trials are few and/or small and/or badly designed. The issue will be how to get funding to conduct these patient-led trials. At the moment, the funders seem to need to have an academic researcher to lead a funding bid to do a trial. Finding a researcher willing to hand over control of trial design before applying for funding is a challenge. This seems to be what CTN Lite will do for ME trials. But it would be great to develop a standard way to allow other patient groups to do the same.
 
A general question on OMF. Does anybody know if it will fund projects that don't include collaboration with any of their existing teams? I see no mention on their website of how to apply for funding, although I could well have missed it, so I am currently assuming not.
 
May 20, 2026: Full-Scale Testing Is Underway

"We’re excited to share that testing on all 1000+ BioQuest samples has officially begun at Nightingale Health, where they are conducting NMR metabolomics and Olink proteomics analyses. But that’s just the beginning. Additional testing will take place at OMF’s collaborative research centers:

Montreal Center
Our Montreal center will perform a cytokine panel, haptoglobin phenotyping, and immunoassays targeting specific molecules identified through previous research— including SMPDL3B, GDF-15, FGF-21, and BDNF. These tests will reveal critical immune system patterns and inflammatory markers, and validate existing findings.

Uppsala Center
Our Uppsala center will carry out mass spectrometry-based proteomics and metabolomics, along with additional immunoassays—adding even deeper layers of biological insight."

Link
 
Last edited:
Back
Top Bottom